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Discussion
Dr Juan Carlos Chachques (Paris, France). I think that this
is a very interesting approach. We know this kind of therapy has
limitations because of work in dynamic cardiomyoplasties during
several years. This device existed 4 or 5 years ago. You have now
a 2-month follow-up without histologic study. We know that
foreign materials positioned around the heart can induce fibrosis
and, secondarily, compression. Do you have histologic evidence at
long term that this device cannot induce high fibrosis and then
diastolic function limitation?
Dr Pilla. In this study, which was terminated at 2 months, there
was no difference in end-diastolic pressure. There was actually a
slight improvement in dP/dtmin in the CSD group; also , the time
constant relaxation, was also slightly improved in the CSD group.
So with respect to diastolic dysfunction, there didn’t seem to be
any at 2 months. We are performing ongoing studies in which the
animals will actually go out to 3 months to look at such issues as
diastolic function and also the histologic and pathologic changes
that occur in the myocardium.
Dr Chachques. This is not long term. Okay, we agree.
Dr Pilla. Relatively long term.
Dr Michael A. Acker (Philadelphia, Pa). Just a follow-up of
your question. In a different model, Hani Sabbah from Henry Ford
has looked at his heart failure dogs as late as 1 year histologically,
and there is the same thin scar formation as is present at 2 months.
So it does not appear in about 6 animals that there was an ongoing
process.
Clinically now there are patients now who have had this jacket
placed for more than 2 years, although again not for acute MI but
for chronic dilated myopathies. There is no evidence in close to
100 patients to date of constriction developing physiologically,
and, a few patients are out over 2 years. Will this develop in 5
years, or 10 years? We don’t know. But there is not any evidence
at this time in animal or in human trials.
Dr Stephen Westaby (Oxford, UK). Can you just speculate
quickly how you would take this forward clinically, because it is
very difficult to see how you would decide to do a thoracotomy
and place this device in a patient who has just had a myocardial
infarction.
Dr Pilla. Actually, they are currently working on minimally
invasive techniques to position the CSD for such reasons as
avoidance of a thoracotomy after MI. So they are addressing those
issues, because we do have the same concerns.
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